Abstract:ABSTRACT The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued, enabling the virus to escape from host immunity by changing its spike antigen, while biased toward the receptor-binding domain and N-terminal domain. Here, we isolated a novel pan-SARS-CoV-2 neutralizing antibody (which we named MO11) for even the recent dominators XBB.1.16 and EG.5.1, from a convalescent patient who had received three doses of an original mRNA COVID-19 vaccination. A cryo-electron microscopy analysis of the spike-MO11 complex at 2.3 Å atomic resolution revealed that it recognizes a conserved epitope hidden behind a glycan shield at N331 on subdomain 1 (SD1), holding both the N- and C-terminal segments comprising SD1. Our identification of MO11 unveiled the functional importance of SD1 for the spike’s function, and we discuss the potential availability of a novel common epitope among the SARS-CoV-2 variants. IMPORTANCE Novel severe acute respiratory syndrome coronavirus 2 variants with immune evasion ability are still repeatedly emerging, nonetheless, a part of immunity developed in responding to the antigen of earlier variants retains efficacy against recent variants irrespective of the numerous mutations. In exploration for the broadly effective antibodies, we identified a cross-neutralizing antibody, named MO11, from the B cells of the convalescent patient. MO11 targets a novel epitope in subdomain 1 (SD1) and was effective against all emerging variants including XBB.1.16 and EG.5.1. The neutralizing activity covering from D614G to EG.5.1 variants was explained by the conservation of the epitope, and it revealed the importance of the subdomain on regulating the function of the antigen for viral infection. Demonstrated identification of the neutralizing antibody that recognizes a conserved epitope implies basal contribution of such group of antibodies for prophylaxis against COVID-19.

Defining a Highly Conserved Cryptic Epitope for Antibody Recognition of SARS-CoV-2 Variants.

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein

A Broadly Neutralizing Antibody Inhibits SARS-CoV-2 Variants Through a Novel Mechanism of Disrupting Spike Trimer Integrity

A Cryptic Site in Class 5 Epitope of SARS-CoV-2 RBD Maintains Highly Conservation Across Natural Isolates

Mapping Cross-Variant Neutralizing Sites on the SARS-CoV-2 Spike Protein.

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants

Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants

Cross-neutralizing Antibodies Bind a SARS-CoV-2 Cryptic Site and Resist Circulating Variants

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen

Identification of Three Conserved Linear B Cell Epitopes on the SARS-CoV-2 Spike Protein

Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants

The immunodominant and neutralization linear epitopes for SARS-CoV-2

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Receptor-binding domain-associated serotypes of SARS-CoV-2

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

A core epitope targeting antibody of SARS-CoV-2